CC
RPTX

Corton Capital’s Repare Therapeutics RPTX Stock Holding History

Corton Capital’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-75,091
Closed -$248K – 641
2024
Q2 		$248K Buy
75,091
+28,868
+62% +$103K 0.13% 261
2024
Q1 		$218K Buy
46,223
+18,383
+66% +$118K 0.08% 390
2023
Q4 		$203K Buy
+27,840
New +$156K 0.06% 470

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Corton Capital's RPTX Position: Q3 2024 in Review

Corton Capital sold out of Repare Therapeutics (RPTX) in Q3 2024, closing a stake of 75,091 shares — an estimated $248K sold.

Corton Capital first reported a position in RPTX in Q4 2023 and held it in 3 quarters. The position peaked at $248K in Q2 2024. 56 funds tracked by Wall St. Rank hold RPTX as of Q3 2024.

  • Corton Capital reported no remaining Repare Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Corton Capital sold 75,091 Repare Therapeutics shares in Q3 2024, an estimated $248K.
  • Corton Capital first reported a position in Repare Therapeutics in Q4 2023 and held it in 3 quarters.
  • Corton Capital's Repare Therapeutics position peaked at $248K in Q2 2024.
  • 56 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2024.

Based on Corton Capital's 13F filing for Q3 2024, filed 14 Nov 2024.